Vion Pharma (VION) Hires Merriman Curhan Ford to Evaluate Strategic Alternatives
More News related to VION
- Vion Pharmaceuticals Issues Management Statement Regarding Trading Volume of Company's Common Stock
- Vion Pharmaceuticals Announces Filing of Special Protocol Assessment for Onrigin(TM)
- U.S. FDA Responds to VION Pharma's (VION) HOVON AML 92 Phase III Evaluation
- Vion Pharmaceuticals Announces FDA Conclusion
- Vion Pharma (VION) Files for Chapter 11 Bankruptcy
More News related to Corporate News
- Shaw Group (SHAW) Awarded Five-YearWorldwide Environmental Remediation Services Contract from U.S. Army CoE
- CB Richard Ellis (CBG) Announces $156M Debt Maturity Extension Reached
- Innodata Isogen (INOD) Announces Corrections to Financial Statements; FY08 Net Income Overstated by $926K
- AVANIR Pharma (AVNR) Gets New Patent for PBA Treatment Zenvia
- optionsXpress (OXPS) Reports Trading Results for January
VION PHARMACEUTICALS, INC. (OTCBB: VION) announced today that it had hired the investment banking firm Merriman Curhan Ford & Co. to assist in evaluating its strategic alternatives. These alternatives include any combination of a restructuring of the Company and its debt and a sale of the Company or its assets. The Company may also consider financing options.
Related Categories
Corporate NewsStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
